March 6, 2008 - Bar Harbor BioTechnology Inc. announced the launch of its new line of human StellARray™ products for gene expression research today. This initial offering of 43 different biological pathways for scientists to select from includes many major human diseases. Configured to perform gene expression or gene copy number experiments these new Real-Time PCR arrays are the first of their kind in the field of gene expression research.
"Scientists researching human diseases like obesity, osteoporosis, and Alzheimer's disease have a new method for detecting subtle changes in how a group of genes are expressed. That could lead to a breakthrough in their research," says Robert Phelps, President of Bar Harbor BioTechnology Inc... Bar Harbor BioTechnology's Press Release -
Blog Archive
-
▼
2008
(55)
-
▼
March
(13)
- Sanofi-aventis : NICE Recommends Acomplia to be in...
- deCODE Obesity Genetics study merck
- Arena Pharmaceuticals' Lorcaserin for Obesity
- VIVUS, Enrollment in EQUATE (OB-301) Trial completed
- Thiakis, Novel therapy for treatment of obesity en...
- Alizyme's cetilistat,Phase III development program...
- Merck, Innovative Research Method to Identify Chan...
- Marcadia Biotech and Merck, strategic collaboration
- Hollis-Eden Pharmaceuticals, Positive Preliminary ...
- Bar Harbor BioTechnology : New Line of StellARrays
- EnteroMedics, Expansion of EMPOWER Pivotal Study f...
- OREXIGEN Therapeutics, European Patent Office Allo...
- Athersys, Results for Phase 1 Safety Study of Its ...
-
▼
March
(13)